TY  - GEN 
AU  - Carles, Joan
AU  - Medina Lopez, Rafael A.
AU  - Puente, Javier
AU  - Gómez Ferrer, Álvaro
AU  - Casas Nebra, Javier
AU  - Sáez Medina, María Isabel
AU  - Ribal, Maria J.
AU  - Rodríguez Antolín, Alfredo
AU  - Álvarez-Ossorio Fernández, José Luis
AU  - Suárez Novo, José Francisco
AU  - Moretones Agut, Cristina
AU  - Srinivasan, Shankar
AU  - Ortiz, Jorge
AU  - Fizazi, Karim
A4  - Cirugía
PY  - 2023
SN  - 1479-6694
UR  - http://hdl.handle.net/10498/31131
AB  - Aim: Darolutamide significantly prolonged metastasis-free survival (MFS) versus placebo in the Phase III ARAMIS study. We analyzed outcomes in Spanish participants in ARAMIS. Patients & methods: Patients with high-risk nonmetastatic...
LA  - eng
PB  - Newlands Press
KW  - androgen receptor inhibitor
KW  - castration-resistant prostate cancer
KW  - darolutamide
KW  - metastasis-free survival
KW  - nonmetastatic
KW  - prostate-specific antigen
KW  - PSA progression
KW  - Spain
KW  - Spanish
TI  - Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis
DO  - 10.2217/fon-2022-1131
ER  -